Prescient Therapeutics (ASX:PTX) secured investigational new drug clearance from the US Food and Drug Administration to conduct a phase two trial of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas, according to a Monday filing with the Australian bourse.
The two-part trial will investigate the optimal dose of PTX-100 and its efficacy, the filing said. It will be conducted across 15 global trial sites.
The company's shares fell 4% in recent Friday trade.
Price (AUD): $0.05, Change: $-0.002, Percent Change: -4.08%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。